LAGUNA NIGUEL, Calif.--(BUSINESS WIRE)--Aeolus Pharmaceuticals, Inc. (OTC Bulletin Board: AOLS) reported that researchers from National Jewish Research and Medical Center and the University of Colorado have completed a series of studies demonstrating that AEOL 10150 provides statistically significant protection of the lungs and skin in the 2-chloroethyl-ethylsulfide (CEES; half mustard) model of mustard gas exposure in rats. Data were presented at the National Institute of Health’s CounterACT Countermeasures Against Chemical Threats Conference in Washington DC. There are currently no effective treatments for mustard gas exposure, and AEOL 10150 is a major focus of a sponsored research grant awarded by the NIH Counteract program to National Jewish to identify an effective treatment.
